News & Events
September 26, 2024
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome Download this news article Read More Read MoreJanuary 5, 2023
Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member Download this news article Read More Read MoreJanuary 3, 2023
Minovia Therapeutics to Present at Biotech Showcase on J.P. Morgan Healthcare week Download this news article Read More Read MoreDecember 21, 2022
Minovia Therapeutics Reports in Science Translational Medicine on First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases Download this news article Read More Read MoreDecember 21, 2022
In a first, children with rare genetic diseases get mitochondrial transplants from their mothers Download this news article Read More Read MoreFebruary 28, 2022
The Israeli Company That Develops Treatment for Rare Diseases [Hebrew article] Download this news article Read More Read More
Minovia to Present at Piper Sandler Healthcare Conference for Private Companies on November 29, 2021 Download this news article
Read More
Read More
September 24, 2021
Minovia’s Preclinical Publication in Nature’s Journal of Regenerative Medicine on the Benefit Conferred by Mitochondrially-augmenetd CD34+ Cells in Patients with Mitochondrial Disorders Download this news article Read More Read MoreJuly 30, 2021
Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs Read More Read More